Buscar
Congreso SOLACI

Búsqueda de: atrial fibrillation

Si no está conforme con los resultados, inténtelo de nuevamente.
Antithrombotic Anticoagulants

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series....
Dr. Carlos Fava -
Ir
Acute coronary syndromes

Recently Diagnosed Atrial Fibrillation in Patients with Acute Coronary Syndrome: Results of the FORCE-ACS Registry

Atrial fibrillation (AF) is a common condition in patients with acute coronary syndrome (ACS). About 10% of...
Dr. Carlos Fava -
Ir
Antiplatelet

AHA 2023 | Use of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Subclinical atrial fibrillation (AF), generally asymptomatic and of short duration, often requires continuous long-term monitoring using pacemakers...
solaci -
Ir
Antithrombotic Anticoagulants

AFIRE Study | Hidden Risks After Bleeding in Coronary Disease and Atrial Fibrillation

Patients with atrial fibrillation (AF) and stable coronary disease who suffer from major bleeding present an extremely...
solaci -
Ir
Antithrombotic Anticoagulants

Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?

Atrial fibrillation is a risk factor for dementia and anticoagulant agents have been proven to decrease it....
solaci -
Ir
Antithrombotic Anticoagulants

AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?

Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) will benefit from rivaroxaban monotherapy both in terms...
solaci -
Ir
Antiplatelet

ESC 2021 | ENVISAGE-TAVI AF: Surprise with Endoxaban in TAVR and Atrial Fibrillation

The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when...
solaci -
Ir
Other

Differences in American and European Atrial Fibrillation Guidelines

The recent publication of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC)...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

Dr. Omar Tupayachi - 0
While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Dr. Andrés Rodríguez - 0
Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Dr. Omar Tupayachi - 0
Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Noticias Institucionales

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

The El Salvador 2024 Sessions are coming soon

solaci - 0
The XLIX SOLACI 2024 Regional Sessions (17th Central America & the Caribbean) are approaching, and will take place in the city of San Salvador (El Salvador)....

Check out the best images of the Arequipa 2024 Sessions

solaci - 0
Review the highlights of the XVIII SOLACI Regional Sessions held at the Hanan Hotel in Arequipa, Peru between October 3 and 4, 2024. <!-- wp:tw/bwg...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad